VANCOUVER, B.C., July 6, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) today announced results from two studies designed to assess the therapeutic potential of its Transcend vector in treating metastatic breast cancer. In these studies trastuzumab (tradename Herceptin), a humanized monoclonal antibody used clinically in the treatment of HER2-positive (“HER2+") breast cancer, was chemically linked to the Transcend delivery vector. The purpose of these studies was to assess if this conjugate can cross the blood-brain barrier and enter the tissue of the brain. And further, to test the effectiveness of the Transcend-trastuzumab conjugate (known as BT2111) against HER2+ cancer cells, verses trastuzumab on its own.
